TVTX
Travere Therapeutics, Inc. (TVTX) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
Gross margin remains very high at 94.4%, but operating profitability is still negative with EBIT margin at -9.7% and net margin at -7.4%.
Returns remain deeply negative, with ROIC at -6.2%, ROE at -55.8%, and ROA at -5.4%, indicating no durable earnings power yet.
Balance Sheet Financial Strength
Liquidity is solid with a current ratio of 4.0 and quick ratio of 4.0, providing near-term flexibility.
Leverage remains very high, with debt-to-equity at 25.2x and net debt to EBITDA at 323.3x, which limits financial resilience.
Pricing Power Unit Economics
Gross margin of 94.4% suggests strong product-level pricing economics, but that has not translated into positive operating margins.
Cash conversion is positive, with operating cash flow margin at 15.7% and free cash flow margin implied by FCF yield, but valuation remains extremely demanding at 10.5x sales and 111.0x free cash flow.
Competitive Positioning
The business shows some moat-like characteristics in its high gross margin and strong fixed-asset turnover, but the lack of profitability weakens evidence of a durable competitive advantage.
Heavy R&D spend at 38.4% of revenue indicates continued investment, but it also underscores that the moat is still being built rather than fully proven.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Travere Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

